Avadel Pharmaceuticals PLC is a drug manufacturers-specialty & generic business based in the US. Avadel Pharmaceuticals shares (AVDL) are listed on the NASDAQ and all prices are listed in US Dollars. Avadel Pharmaceuticals employs 66 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.57 |
|---|---|
| 52-week range | $1.05 - $11.59 |
| 50-day moving average | $3.39 |
| 200-day moving average | $6.83 |
| Wall St. target price | $9.30 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.57 from 2022-07-01
| 1 week (2022-06-27) | 5.76% |
|---|---|
| 1 month (2022-06-03) | 4.05% |
| 3 months (2022-04-05) | -61.58% |
| 6 months (2022-01-05) | -66.49% |
| 1 year (2021-07-02) | -64.55% |
|---|---|
| 2 years (2020-07-02) | -67.75% |
| 3 years (2019-07-05) | 15.77% |
| 5 years (2017-07-03) | 11.09 |
Valuing Avadel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avadel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avadel Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Avadel Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Gross profit TTM | $16.6 million |
|---|---|
| Return on assets TTM | -24.16% |
| Return on equity TTM | -94.2% |
| Profit margin | 0% |
| Book value | $0.94 |
| Market capitalisation | $151.7 million |
TTM: trailing 12 months
We're not expecting Avadel Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Avadel Pharmaceuticals's shares have ranged in value from as little as $1.05 up to $11.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avadel Pharmaceuticals's is 1.1697. This would suggest that Avadel Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.